Document |
Document Title |
WO/2017/028732A1 |
Disclosed are a preparation method of an orexin receptor antagonist compound 5-3, crystalline forms I-IV of the compound and preparation method thereof, and application of the crystalline forms in preparation of a drug treating a disease...
|
WO/2017/025849A1 |
Compounds, tautomers and pharmaceutically acceptable salts of the compounds of Formula (Ia) are disclosed which are inhibitors of lnterleukin-1 receptor associated kinase (IRAK4). Methods of treatment, methods of synthesis, and intermedi...
|
WO/2017/018409A1 |
Provided is a compound represented by formula (I). In formula (I), A- represents a halogen ion, a benzenesulfonate ion, an alkylsulfonate ion, or the like, X represents a halogeno group or the like, a is an integer of 0-4, Y represents a...
|
WO/2017/004454A1 |
Disclosed herein are methods for use of R-chloroquine or clemizole or combinations of R- chloroquine and clemizole for the treatment of a subject in need thereof. Uses include methods of treating inflammatory' conditions, treating liver ...
|
WO/2017/004522A1 |
Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).
|
WO/2016/203112A1 |
The present invention provides novel spiro[cyclobutane-1,3'-indolin]-2'- derivatives of formula (I) in which Cy R1, R2, R4, L and 'm' are have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The com...
|
WO/2016/166604A1 |
Provided herein, inter alia, are compounds and methods for inhibiting PLK4 and for treating cancer in a subject in need thereof.
|
WO/2016/082403A1 |
The invention relates to the field of compound synthesis, and mainly relates to a class of difluoro methylene piperidine carboxamide derivatives (I), a pharmaceutical composition containing same, and a preparation method and use thereof,...
|
WO/2016/081679A1 |
The present invention relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, useful as IRAK inhibitors.
|
WO/2016/050567A1 |
A compound of formula (I), wherein A and R1 are as defined in claim 1. Furthermore, the present invention relates to intermediates used to prepare compounds of formula (I), to methods of using them to combat and control insect, acarine, ...
|
WO/2016/039048A1 |
The present invention provides a compound which is represented by formula (I-1) (wherein R4 represents a hydrogen atom, a C1-6 alkyl group or the like; Ar1 represents a C6-10 aryl group, a 3-6 membered heterocyclyl group or the like; A r...
|
WO/2016/027780A1 |
A compound represented by formula (I), or a pharmaceutically acceptable salt thereof, acts as an FGFR inhibitor. [In the formula: A represents a C6-10 arylene group or the like that may have a substituent; J represents a C3-10 nitrogen-c...
|
WO/2016/016692A1 |
A process for the production of atropine is provided. The process provides for a new, efficient and commercially feasible synthetic process for the preparation of atropine and atropine salts. In one aspect, a one pot process for the synt...
|
WO/2015/199206A1 |
The present invention relates to a compound represented by formula (I), a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound or the salt. (In the formula, R1 represents a hydrogen atom or t...
|
WO/2015/182724A1 |
Provided are compounds that are useful as prophylactic or therapeutic agents for various diseases involving T-type calcium channels, such as hypertension, arrhythmia, pain and cancer, said compounds having antagonistic activity against T...
|
WO/2015/162558A1 |
The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in the treatment of an ATX-dependent or ATX-med...
|
WO/2015/131773A1 |
The present invention discloses a series of piperidine derivatives as orexin receptor antagonists and compositions thereof, and relates to the application thereof in preparing medications for the treatment of insomnia, chronic obstructiv...
|
WO/2015/128440A1 |
A cocrystal of tiotropium bromide and lactose monohydrate is herein disclosed. In the cocrystal the components tiotropium bromide and lactose are preferably present in an almost stoichiometric ratio. Said cocrystal has a single endotherm...
|
WO/2015/119099A1 |
The present invention obtains a compound indicated by formula (I) or a salt thereof. The present invention also obtains an agricultural and horticultural fungicide, a pest control agent, or a pesticide or miticide, that contains as the e...
|
WO/2015/109451A1 |
The present invention mainly pertains to catalytic processes for the direct amination of 2, -bis(hydroxymethyl) tetrahydrofuran to obtain compounds containing the 8-oxa-3-azabicyclo (3.2.1) octane ring, in the presence of: a homogenous c...
|
WO/2015/106058A1 |
The present invention provides compounds of Formula (II) for the treatment of cancer, rheumatoid arthritis and other diseases.
|
WO/2015/101265A1 |
Provided are 1-(3-aminopropyl) substituted cyclic amine compounds as represented by formula (I), pharmaceutically acceptable salts, enantiomers, diastereoisomers, racemates and mixtures thereof, and a method of synthesizing said 1-(3-ami...
|
WO/2015/089809A1 |
The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, pre...
|
WO/2015/089137A1 |
The present invention is directed to acylguanidines which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPHl), that are useful in the treatment of diseases or disorders associated with peripheral serotonin inclu...
|
WO/2015/068773A1 |
Provided is an agricultural and horticultural fungicide manifesting a high control effect against a wide range of plant pathogens. The present invention is a compound represented by formula (I) or a salt thereof, an agricultural and hort...
|
WO/2015/070091A1 |
Compounds of the formulas are provided: wherein variables Y1-Y5, X1-X5, A1-A4, x, y, n1, n2, and R1-R15 are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are are usefu...
|
WO/2015/052264A1 |
The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical c...
|
WO/2015/046193A1 |
The present invention relates to a compound represented by formula (I) (In the formula, R1 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclic group, etc., X is -N(R2)-, -O- or -S-, Y...
|
WO/2015/048250A1 |
The invention generally provides processes for the preparation of radioiodinated 3-fluoropropyl-nor-β-CIT. In particular, the process uses an arylsilane intermediate, thus avoiding the use of hexamethylditin, and reducing the number of ...
|
WO/2015/032617A1 |
A compound of formula I, (I), wherein A, Q, R1, and R2, are as defined in claim 1. Furthermore, the present invention relates to intermediates used to prepare compounds of formula (I), to methods of using them to combat and control insec...
|
WO/2015/033753A1 |
Provided is a method that makes it possible to obtain an endo-9-azabicyclo[3.3.1]nonane-3-ol derivative that is useful as an intermediate of agricultural and horticultural chemicals or pharmaceuticals at a low cost by reacting a 9-azabic...
|
WO/2014/173375A1 |
A process for the synthesis of Maraviroc The invention relates to a new approach to synthesis of Maraviroc, a substance with the chemical name N-{(lS)-3-[3-(3-isopropy)-5- methyl-4 H-l,2,4-triazol-4-yl-exo-8-azabicyclo-[3.2.1]oct-8-yl]-l...
|
WO/2014/042605A9 |
The present invention is related to crystalline compound comprising Tiotropium bromide and the process that shall be used in production of said compound.
|
WO/2014/164682A1 |
A compound, (4s)-1-azaadamantane-4yl formate ester, is described. In addition, a process is described for preparing (4s)-1-azaadamantane-4yl formate ester, aminothiadiazole-phenyl phosphate salt, bromothiadizole-phenyl or (4s)-4-(5-pheny...
|
WO/2014/154486A1 |
The invention relates to a method of controlling insects (in particular insects of the order Hemiptera, especially aphids and whitefly) that are resistant to neonicotinoid insecticides, to methods of controlling insects whereby undesired...
|
WO/2014/154488A1 |
The present invention relates to a method of controlling insects (in particular insects of the order Hemiptera, especially aphids and whitefly) that are resistant to neonicotinoid insecticides, to methods of controlling insects whereby u...
|
WO/2014/154487A1 |
The invention relates to a method of controlling insects (in particular insects of the order Hemiptera, especially aphids and whitefly) that are resistant to neonicotinoid insecticides, to methods of controlling insects whereby undesired...
|
WO/2014/152144A1 |
Compounds of formula (I) and methods are provided for the treatment of disease or conditions in which modification of cholinergic, especially muscarinic receptor activity, has a beneficial effect.
|
WO/2014/140318A1 |
The present invention relates to a novel process for the preparation of esters like Aclidinium, Atropin, Glycopyrroniunn, Tiotropium, Trospium and their respective precursors and derivatives, based on direct acyl transfer reactions.
|
WO/2014/128067A1 |
The invention relates to BET protein-inhibiting, in particular BRD4-inhibiting, bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines of the general formula (I), to the pharmaceutical agents containing the compo...
|
WO/2014/128486A1 |
Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases ΙΚΚε and/or TBK-1 in which one of V and W is N, and the other of V and W is C-H; ...
|
WO/2014/122067A1 |
The present invention relates to compounds of general formula I, (I) wherein the group R1 is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the G-protein coupled receptor 40 (GPR40, also know...
|
WO/2014/102589A1 |
The present disclosure relates to Quinazolin-4(3H)-one-Type Piperidine Compounds, such as those of Formule (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, Q, Y1, Z, A, B, E, and a are as defined he...
|
WO/2014/102829A1 |
The present invention relates to crystalline polymorph form of Atropine sulfate and process for the preparation thereof.
|
WO/2014/092100A1 |
The purpose of the invention is to provide a compound or salt thereof that is useful as an agent for the prevention or treatment of epilepsy, neurodegenerative disease, and the like. The invention pertains to compounds represented by for...
|
WO/2014/078611A1 |
The present invention provides compounds of Formula (I): (Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled rece...
|
WO/2014/067499A1 |
A method for stabilization of micronized or milled solvates of tiotropium bromide, in which the solvates are deposited in a saturated atmosphere of the adequate solvent for the time period sufficient for recovery of the original amount o...
|
WO/2014/063587A1 |
The present invention relates to the field of pharmaceutical chemistry and pharmacotherapeutics, and in particular to compounds of general formula I, racemates, R-isomers, S-isomers, and pharmaceutically acceptable salts thereof and thei...
|
WO/2014/056083A1 |
The invention is a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represen...
|
WO/2014/054053A1 |
The present disclosure relates to a series of spirocyclic compounds of formula (I), their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates, hydrates, N-Oxides, Co crystals and formulations there...
|